Arora Usha, Sonal G S, Dhillon G P S, Thakor Hitendrasinh G
National Vector Borne Disease Control Programme, Ministry of Health and Family Welfare, Government of India, Delhi.
J Indian Med Assoc. 2008 Oct;106(10):678-81, 683.
Chloroquine resistance in Plasmodium malaria is an emerging problem globally. In India resistance of Plasmodium falciparum to choloroquine, the cheapest and the most used drug was first reported in the year 1973 from Diphu of Karbi-Anglong district in Assam state. Systematic monitoring of drug resistance is being undertaken in the country from 1978 by the Directorate of National Vector Borne Disease Control Programme (NVBDCP) through its 13 Pf monitoring teams. The findings of these drug resistance studies has helped the programme for the revision of the drug policy and update it from time to time thereby facilitating appropriate measures for not only individual cases but also to contain and prevent further spread of resistant foci. This article summarises therapeutic efficacy studies conducted by the Pf monitoring teams in the country between 2001 and 2007 related to efficacy of chloroquine and other antimalarials drugs. As per the results available, the efficacy of chloroquine for treating uncomplicated falciparum at most of the study sites is much lower than the desired cut off levels of 10% (83% studies have shown treatment failure more than 10%). Total of 4273, 168 and 137 P. falciparum cases have been tested against chloroquine, sulphadoxine/pyrimethamine and ACT(AS+SP) combination. During the period under report, 85 new chloroquine resistant PHCs/foci from 64 districts were qualified warranting change of drug policy as per the national guidelines. These studies show that chloroquine resistance in P. falciparum is widespread in the country. To combat the drug resistant in malaria, the use of combination therapy ie, artesunate plus sulfadoxine/pyrimethamine has been recommended for treatment of all confirmed P. falciparum cases in all the qualified areas as per the criteria laid down in National Drug Policy on malaria.
恶性疟原虫对氯喹的耐药性是全球范围内一个新出现的问题。在印度,1973年首次在阿萨姆邦卡尔比-安隆地区的迪普胡报道了恶性疟原虫对最便宜且使用最广泛的药物氯喹产生耐药性。自1978年起,国家媒介传播疾病控制项目局(NVBDCP)通过其13个恶性疟原虫监测团队在该国开展耐药性的系统监测。这些耐药性研究的结果有助于该项目修订药物政策并适时更新,从而不仅为个别病例采取适当措施,还能控制和防止耐药病灶的进一步传播。本文总结了2001年至2007年间该国恶性疟原虫监测团队进行的与氯喹及其他抗疟药物疗效相关的治疗效果研究。根据现有结果,在大多数研究地点,氯喹治疗非复杂性恶性疟的疗效远低于预期的10%的临界水平(83%的研究显示治疗失败率超过10%)。总共对4273例、168例和137例恶性疟原虫病例进行了氯喹、磺胺多辛/乙胺嘧啶和ACT(青蒿琥酯+磺胺多辛/乙胺嘧啶)联合用药的检测。在报告所述期间,来自64个地区的85个新的氯喹耐药初级卫生保健中心/病灶符合条件,需要根据国家指南改变药物政策。这些研究表明,恶性疟原虫对氯喹的耐药性在该国广泛存在。为应对疟疾耐药性问题,根据国家疟疾药物政策规定的标准,已建议在所有符合条件的地区对所有确诊的恶性疟病例使用联合疗法,即青蒿琥酯加磺胺多辛/乙胺嘧啶进行治疗。